Relay passes on the lirafugratinib baton
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Nerviano becomes a targeted PARP player
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Kyowa buys into menin, but it's not Syndax's
Syndax scored the first menin approval, but Kura is first with a licensing deal.
